|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: ---------- Conduit Holdings Ltd - parent company of Bermuda-based reinsurer Conduit Re - Chief Financial Officer Elaine Whelan announces her intention to retire, and will step down with effect from September 30. Conduit says she will stay in the role to support the transition to her successor, whom the board has started its formal process to identify. ---------- Ferrexpo PLC - Baar, Switzerland-based iron ore producer in Ukraine - Reiterates its belief that an equity fundraise of at least $100 million is currently the only viable solution to meet its ongoing obligations and provide sufficient working capital for near-term operational requirements. Says it has received indicative, non-binding expressions of interest from institutional investors to provide funding which would exceed $100 million, but that these are ‘conditional on certain terms and conditions of the intended fundraise which are not possible to achieve within the timeframe required.’ Ferrexpo has also been in talks with Fevamotinico Sarl, its largest shareholder with a 49.32% stake, which has confirmed its support for the intended fundraise. Fevamotinico will provide an irrevocable undertaking to vote in favour of the necessary resolutions at a general meeting, if it can participate in a fundraise no greater than $100 million on a pro rata basis. Ferrexpo says it continues to engage with existing and potential investors, but that there is no certainty that it will be successful in executing any funding solution. Adds that it will not be able to publish its 2025 audited financial results by Thursday, and therefore expects its shares to be suspended from trading on Friday. ---------- Seraphim Space Investment Trust PLC - London-based investor in ’SpaceTech’ companies - Portfolio company HawkEye 360 Inc submits its amended registration statement with the US Securities & Exchange Commission for a proposed initial public offering, with a fully diluted estimated equity valuation of approximately $2.36 billion and an expected IPO price range of $24 to $26 per share. Says HawkEye has the potential to raise approximately $400 million with an implied post-money valuation of approximately $2.76 billion. Seraphim says its investment in HawkEye amounts to 10.1% of its net asset value as at December 31, and the $25 IPO price range midpoint gives its holding an implied valuation of approximately $60.8 million, with an indicative uplift to the NAV of about $11.1 million or 4.66 pence per share. ---------- Scancell Holdings PLC - Oxford-based pharmaceutical company focused on cancer immunotherapies - US Food & Drug Administration grants fast track designation for iSCIB1+, its lead ’ImmunoBody’, as a treatment for advanced melanoma. Says progression-free survival for iSCIB1+ has matured positively, reaching 77% at 20 months in the target population, widening the medication’s lead over the PFS reported with ipilimumab plus nivolumab alone. Expects further PFS data and early overall survival data from the phase 2 Scope study in the first half of 2027. ‘This designation is a major achievement for Scancell and important recognition not only of the potential of iSCIB1+, but also of the significant need for new and improved treatment options for patients with advanced melanoma. We are very pleased with how the Phase 2 SCOPE data is maturing and are advancing plans for a global registrational Phase 3 trial, which we expect to initiate in the second half of 2026,’ comments Chief Executive Officer Phil L’Huillier. ---------- Genflow Biosciences PLC - London-based biotechnology firm - Expands its engagement with participants in the global animal health sector, entering ‘additional confidential agreements with tier-1 global animal health companies in connection with the ongoing review of data from its canine SIRT6 cent gene therapy programme.’ Says the agreements entered so far reflect a broadening base of third-party evaluation of its data and technology. Notes that the engagement remains ‘exploratory in nature’ but supports ‘an ongoing evaluation process’. ---------- Mila Resources PLC - gold exploration firm focused on Australia - Says new results from the first-quarter reverse circulation drilling campaign at the Yarrol gold project have returned ‘the highest-grade gold intercept recorded on the project’ of 112 grams per tonne over one metre. ‘Drillholes confirm high grade mineralisation in southernmost positions drilled to date at Yarrol North Target,’ Mila says. ‘The results also confirm extensions of shallow gold mineralisation further to the north and continuity of mineralisation to the west that was not included in the historic resource.’ Says it will report further results from infill and step-out holes in due course, and is using multi-element geochemical assays to refine its structural interpretation of the Yarrol system and to inform next-phase drill targeting. ‘What is emerging is a pattern of repeating structures hosting high-grade shoots, suggesting a more continuous and robust mineralised system than was ever previously understood,’ says Executive Chair Mark Stephenson. ‘We are now moving beyond isolated results and toward the building a meaningful and economic gold resource in a proven gold district. Following our recent capital raise we will be continuing to fast track the development of this project.’ ---------- Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
